• 1
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 73051.
  • 2
    Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27: 5363.
  • 3
    Lingaratnam S, Slavin MA, Mileshkin L, Burbury K, Solomon B, Koczwara B et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J. 2011; 41b: 11020.
  • 4
    van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005; 41: 137282.
  • 5
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 97995.
  • 6
    Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 97787.
  • 7
    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 98898.
  • 8
    Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Antibiotic prophylaxis in neutropenic patients. Isr Med Assoc J 2007; 9: 4602.
  • 9
    Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107: 174351.
  • 10
    Pascoe J, Steven N. Antibiotics for the prevention of febrile neutropenia. Curr Opin Hematol 2009; 16: 4852.
  • 11
    Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6: 12274.
  • 12
    Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 11118.
  • 13
    Oethinger M, Jellen-Ritter AS, Conrad S, Marre R, Kern WV. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 1998; 26: 37984.
  • 14
    Mihu C, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston K. Escherichia coli resistance to fluoroquinolones at a comprehensive cancer centre. 19th ECCMID. 2009: s9.
  • 15
    Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 24429.
  • 16
    Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 141522.
  • 17
    Monnet DL, MacKenzie FM, Lopez-Lozano JM, Beyaert A, Camacho M, Wilson R et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg Infect Dis 2004; 10: 143241.
  • 18
    Bartlett JG, Perl TM. The new Clostridium difficile – what does it mean? N Engl J Med 2005; 353: 25035.
  • 19
    McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 243341.
  • 20
    Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 125460.
  • 21
    Cook PP, Catrou P, Gooch M, Holbert D. Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006; 64: 34851.
  • 22
    Kuijper EJ, van den Berg RJ, Debast S, Visser CE, Veenendaal D, Troelstra A et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006; 12: 82730.
  • 23
    Aldeyab MA, Monnet DL, Lopez-Lozano JM, Hughes CM, Scott MG, Kearney MP et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008; 62: 593600.
  • 24
    Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008; 61: 7218.
  • 25
    Moore C, Dhaliwal J, Tong A, Eden S, Wigston C, Willey B et al. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) acquisition in roommate contacts of patients colonized or infected with MRSA in an acute-care hospital. Infect Control Hosp Epidemiol 2008; 29: 6006.
  • 26
    Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008; 61: 2638.
  • 27
    Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008; 62: 6017.
  • 28
    Debast SB, Vaessen N, Choudry A, Wiegers-Ligtvoet EA, van den Berg RJ, Kuijper EJ. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009; 15: 42734.
  • 29
    Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24: 36286.
  • 30
    Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 8858.
  • 31
    MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005; 11: 1197204.
  • 32
    Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353: 10524.
  • 33
    NCCN. Prevention and Treatment of Cancer-Related Infections. National Comprehensive Cancer Network Practice Guidelines in Oncology. 2008; v.1.2008.
  • 34
    Hammond SP, Baden LR. Antibiotic prophylaxis for patients with acute leukemia. Leuk Lymphoma 2008; 49: 18393.
  • 35
    Turnidge J, McCarthy LR, Master RN, Kepner DE. Low levels of fluoroquinolone resistance in Escherichia coli. A five-year trend in Australia measured through the use of TSN Database Australia. Commun Dis Intell 2003; 27 (Suppl): S8991.
  • 36
    Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010; 116: 96773.
  • 37
    Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 5035.
  • 38
    Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother 2002; 50: 94552.
  • 39
    von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Dohner H et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006; 58: 8914.
  • 40
    Peralta G, Sanchez MB, Garrido JC, De Benito I, Cano ME, Martinez-Martinez L et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60: 85563.
  • 41
    Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003; 97: 41924.
  • 42
    Lautenbach E, Marsicano R, Tolomeo P, Heard M, Serrano S, Stieritz DD. Epidemiology of antimicrobial resistance among gram-negative organisms recovered from patients in a multistate network of long-term care facilities. Infect Control Hosp Epidemiol 2009; 30: 7903.
  • 43
    Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63: 56874.
  • 44
    Kern WV, Pritzkow A, Peyerl-Hoffmann G, von Baum H, Frank U, Dettenkofer M et al. Fluoroquinolone prophylaxis in haematology-oncology patients is it still useful? European Society of Clinical Microbiology and Infectious Diseases. 2009; 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland, 16–19 May 2009.
  • 45
    Wang A, Yang Y, Lu Q, Wang Y, Chen Y, Deng L et al. Presence of qnr gene in Escherichia coli and Klebsiella pneumoniae resistant to ciprofloxacin isolated from pediatric patients in China. BMC Infect Dis 2008; 8: 68.
  • 46
    Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 4738.
  • 47
    Monsen T, Ronnmark M, Olofsson C, Wistrom J. Antibiotic susceptibility of staphylococci isolated in blood cultures in relation to antibiotic consumption in hospital wards. Scand J Infect Dis 1999; 31: 399404.
  • 48
    Gustafsson I, Cars O, Andersson DI. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J Antimicrob Chemother 2003; 52: 25863.
  • 49
    Kern WV, Steib-Bauert M, de With K, Reuter S, Bertz H, Frank U et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005; 55: 5760.
  • 50
    Hedin G, Hambraeus A. Multiply antibiotic-resistant Staphylococcus epidermidis in patients, staff and environment - a one-week survey in a bone marrow transplant unit. J Hosp Infect 1991; 17: 95106.
  • 51
    Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int J Antimicrob Agents 2009; 34: 825.
  • 52
    Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005; 24: 8328.
  • 53
    Guerin F, Varon E, Hoi AB, Gutmann L, Podglajen I. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob Agents Chemother 2000; 44: 2197200.
  • 54
    Rodriguez-Avial I, Rodriguez-Avial C, Culebras E, Picazo JJ. Fluoroquinolone resistance among invasive viridans group streptococci and Streptococcus bovis isolated in Spain. Int J Antimicrob Agents 2007; 29: 47880.
  • 55
    Ip M, Chau SS, Chi F, Tang J, Chan PK. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 2690700.
  • 56
    Paul M, Andreassen S, Tacconelli E, Nielsen AD, Almanasreh N, Frank U et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 2006; 58: 123845.
  • 57
    Johnson JK, Smith G, Lee MS, Venezia RA, Stine OC, Nataro JP et al. The Role of Patient-to-Patient Transmission in the Acquisition of Imipenem-Resistant Pseudomonas aeruginosa Colonization in the Intensive Care Unit. J Infect Dis 2009; 200: 9005.
  • 58
    Harris AD, Perencevich EN, Johnson JK, Paterson DL, Morris JG, Strauss SM et al. Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis 2007; 45: 134750.
  • 59
    Harris AD, Kotetishvili M, Shurland S, Johnson JA, Morris JG, Nemoy LL et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 2007; 35: 97101.
  • 60
    Lautenbach E. Antimicrobial resistance in gram-negative pathogens: crafting the tools necessary to navigate the long ascent out of the abyss. J Infect Dis 2009; 200: 83840.
  • 61
    Pearson J, Turnidge J, Franklin C, Bell J. Prevalence of antimicrobial resistances in common pathogenic Enterobacteriaceae in Australia, 2004: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 2007; 31: 10612.
  • 62
    Turnidge JD, Nimmo GR, Pearson J, Gottlieb T, Collignon PJ. Epidemiology and outcomes for Staphylococcus aureus bacteraemia in Australian hospitals, 2005–06: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 2007; 31: 398403.
  • 63
    Turnidge J. Impact of antibiotic resistance on the treatment of sepsis. Scand J Infect Dis 2003; 35: 67782.
  • 64
    Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989–1999. Microb Drug Resist 2003; 9: 15560.
  • 65
    Lautenbach E, Metlay JP, Weiner MG, Bilker WB, Tolomeo P, Mao X et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009; 30: 1824.
  • 66
    Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357(17): 170515.
  • 67
    von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B et al. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008; 19: 2928.
  • 68
    Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 230213.
  • 69
    Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17: 120512.